Evidence review · standard

cerebrolysin

bundle · json · system map · manifest

Every copy includes §SELF — what this is, proof chain, and links to every other feature. No context required.

§SELF — this page explains the system
## §SELF — miscsubjects (paste without context)

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `human_page` — **Human article page**
Rendered article with claims, sources, copy widgets, ask prompts.
- **article slug:** `cerebrolysin`
- **contains:** rendered article, copy widgets, claims, sources, ask prompts
- **how to use:** Use Copy for LLM or Copy system map — both paste without context.
- **read:** https://miscsubjects.com/a/cerebrolysin

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/cerebrolysin/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **bundle** — Paste-ready package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/cerebrolysin/bundle?format=markdown
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/cerebrolysin/prompts
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/cerebrolysin/topology

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

*Not medical advice. Tier-honest. Cite claim/source ids.*

Regeneration vs degeneration — where this fits

The body is always doing two things at once: breaking down (degeneration) and building back (regeneration). A condition persists when breakdown outruns repair. Most drugs used for symptoms suppress a signal (pain, acid, anxiety, inflammation) without fixing the tissue that caused the signal. Peptides in this ledger are studied for repair pathways: new blood vessels, repair-cell migration, nerve regrowth, gut lining, neural connections. This article maps one compound through that frame — what it is, how it is proposed to work, what evidence exists, and what people report.

Why it would work (logic chain)

No mechanism chain catalogued yet.

How many people take it

There is no reliable global count of how many people take this compound. That number is not in this ledger.

What we can count from this ledger:

  • 0 anecdote source(s) (posts, threads, comments)
  • 0 anecdote-tier claim(s) derived from them

Logic: Without catalogued Reddit/X posts, this article cannot answer how many people take it — only what studies exist.

Evidence inventory

This is a count of what is in this ledger — not a claim about all research worldwide.

  • Scientific sources catalogued (PubMed, trials, reviews): 9
  • Claims tagged human evidence: 0
  • Claims tagged preclinical (animal/lab): 0
  • Claims tagged anecdotal: 0
  • Reddit posts catalogued: 0
  • X posts catalogued: 0
  • Other anecdote sources (YouTube, Instagram, etc.): 0
  • Total sources in chain: 9

Logic: Studies exist in the ledger, but none are graded as strong human proof for the uses people discuss online. Animal and lab work is not the same as proof in people.

Logic: No social posts catalogued yet — we cannot report what people are saying on Reddit or X from this ledger.

Quantified confidence (this ledger): 0.23 / 1.00 — low — animal and anecdote heavy

Formula: human claims×0.12 + preclinical×0.04 + anecdote×0.015 + studies (capped). This is not clinical certainty — it measures how much graded evidence is catalogued here.

What scientists say

The possible role of cerebrolysin in the management of vascular dementia: Leveraging concepts (source s1)

2025 review discussing Cerebrolysin (CBL) as a potential treatment for vascular dementia via anti-inflammatory and neuroprotective mechanisms.

Evidence type: Published research.

Speech Therapy Combined With Cerebrolysin in Enhancing Nonfluent Aphasia Recovery After Acute Ischemic Stroke: ESCAS Randomized Pilot Study (source s2)

2025 randomized pilot study (ESCAS) showing benefits of Cerebrolysin plus speech therapy for post-stroke aphasia recovery.

Evidence type: Published research.

Effects of Cerebrolysin on Language Ability in Non-fluent Aphasia After Stroke (source s3)

Ongoing 2025 clinical trial evaluating Cerebrolysin for language recovery in post-stroke non-fluent aphasia.

Evidence type: Published research.

Cerebrolysin in Critically Ill Patients With Delirium (source s4)

2025 clinical trial testing Cerebrolysin for reducing delirium severity in critically ill patients.

Evidence type: Published research.

Safety and Efficacy of Cerebrolysin for Neurorecovery After Acute Ischemic Stroke (source s5)

2025 study/meta-analysis supporting Cerebrolysin for improved neurorecovery post-ischemic stroke.

Evidence type: Published research.

C-REGS2-A multinational, high-quality comparative ... (source s6)

2025 real-world study (C-REGS2) confirming efficacy and safety of Cerebrolysin in acute ischemic stroke.

Evidence type: Published research.

Efficacy of Cerebrolysin Treatment as an Add-On Therapy to Mechanical Thrombectomy in Patients with Acute Ischemic Stroke Due to Large Vessel Occlusion in Anterior Circulation: Results of a 3-Month Follow-up of a Prospective, Open Label, Single-Center Study (source s7)

2025 study showing benefits of Cerebrolysin as add-on to mechanical thrombectomy in acute ischemic stroke.

Evidence type: Published research.

Evaluating the Effect of Cerebrolysin as an Adjuvant to Standard Therapy in Patients with Acute Ischemic Stroke: A Prospective Observational Study (source s8)

2025 prospective observational study on Cerebrolysin adjuvant in acute ischemic stroke.

Evidence type: Published research.

Cerebroprotection in acute ischemic stroke: Perspectives on combining Cerebrolysin with recanalization therapy (source s9)

2025/2026 perspectives/review on Cerebrolysin with recanalization in AIS.

Evidence type: Published research.

---

Not medical advice. Counts and quotes are from this article's hash-chained ledger. Anecdote = real reports, not proof. Animal studies ≠ human proof.

Cerebrolysin · peptide map

Evidence map

Hover a node — its path lights up. Click to open the article.

Full map →
JumpMetformin
Evidence · 9 sources · swipe →chain b24406f09d2a · verify chain · provenance
1 / 9
Model swipes · 3 from 1 model · swipe →verify
1 / 3
grok-4.3writer
draft2026-06-29 16:53
cerebrolysin
inspect — what it was prompted & output
prompted with
(default writer prompt)
e5cdf02f89b701a8
grok-4.3source_hunt
sources2026-06-29 16:54
6 source(s) added · 6 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: cerebrolysin
it output
3 source(s) added
3124f8727002d44a
grok-4.3source_hunt
sources2026-06-29 16:54
3 source(s) added · 3 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: cerebrolysin
it output
3 source(s) added
79b06fc59030de30

Related research

Cerebrolysin · peptide map

Open evidence map →
Metformincerebrolysin-metformin
Ask this article · 2 suggested prompts
topology · JSON · question graph

Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.

For my medical situation, what can you answer from your catalogue about cerebrolysin — and what would you need me to tell you first?
ask cerebrolysin condition gaps · paste includes §SELF
What good and bad outcomes are documented for cerebrolysin (studies vs anecdotes)?
ask cerebrolysin good bad experiences · paste includes §SELF
cerebrolysin · posted 2026-06-29 · updated 2026-06-29 · 2 prior revisions
Ledger API & provenance
Provenance · 3 model passes · 0 tokens · $0 · 1 model
chain head 24a04290baac6e60
populate-init grok-4.3 · 2026-06-29 16:53 · 0 tok · cf4e7d7fcdfd
sources grok-4.3 · 2026-06-29 16:54 · 0 tok · 660b764ee2a8
sources grok-4.3 · 2026-06-29 16:54 · 0 tok · 24a04290baac
verify chain →
REST + ledger
read GET /api/articles/cerebrolysin · GET /api/articles/cerebrolysin?format=post (the editable body)
create/replace POST /api/articles/cerebrolysin · PUT /api/articles/cerebrolysin (replace, keeps revision) · PATCH /api/articles/cerebrolysin (merge)
delete DELETE /api/articles/cerebrolysin
writes need header x-terminal-key
ledger provenance · sources · contributions · revisions · live ledger & cards
LLM bundle GET /api/articles/cerebrolysin/bundle?format=markdown — body + claims + sources + provenance + manifest
voxel graph GET /api/articles/cerebrolysin/voxels · constitution · ontology
post claim POST /api/protocol/claim · iMessage claim cerebrolysin|tier|assertion
system map GET /api/articles/system-map?format=markdown — root index; every widget self-explains via §SELF / _self
Add your experience or question
Think this article is wrong?
Call bullshit on CharlieOS →